Microdosing GLP-1 Medications Compare split-dosing across all GLP-1 agonists

Researchers theorize this may be because: GIP activation may counterbalance some GLP-1 effects on the gut Dose escalation schedule allows more gradual adaptation Different pharmacokinetic profile may produce less pronounced peaks Serious Side Effects (Both Medications): These are rare but require immediate medical attention: Pancreatitis: Severe abdominal pain that may radiate to the back Risk: Less than 1% with both medications Usually occurs in first few months of treatment Requires immediate discontinuation if suspected Gallbladder Problems: Gallstones, cholecystitis (gallbladder inflammation) Symptoms: Right upper abdominal pain, nausea, fever More common with rapid weight loss May require surgical intervention Kidney Problems: Dehydration from vomiting/diarrhea can affect kidney function Watch for decreased urination, swelling in legs Stay well-hydrated, especially during side effect periods Thyroid Tumors (Black Box Warning): Both medications carry warnings about thyroid C-cell tumors Based on rodent studies

Some online weight loss providers use compounded or lower-quality medications with questionable effectiveness
Lancet 10-23-1976;2(7991):905
This means a 10-unit injection from a 5mg/mL vial gives you 0.5 mg of semaglutide
We dive into new research on GLP-1 persistence, the early challenges facing Medicare's obesity drug rollout, and why pharmaceutical companies are racing to solve the problems patients have been talking about for years